Vol. 4 No. 5 (2024): May
Reimbursement Recommendations

Cannabidiol (Epidiolex)

decorative image of the issue cover

Published May 7, 2024

Key Messages

  • CADTH recommends that Epidiolex should be reimbursed by public drug plans as adjunctive therapy for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients aged 2 years and older if certain conditions are met.
  • Epidiolex should only be covered for the treatment of patients who are aged 2 years and older with seizures caused by TSC despite receiving other antiseizure medications.
  • Epidiolex should only be reimbursed in patients who have at least 8 seizures over a 28-day period that are not controlled despite receiving 2 or more antiseizure medications if it is prescribed by physicians with experience in the diagnosis and management of patients living with TSC and if the cost of Epidiolex is reduced. Epidiolex should not be reimbursed for use in combination with mTOR inhibitors or recreational or medicinal cannabis.